File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency

TitleLong term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency
Authors
Issue Date1988
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal Of Clinical Endocrinology And Metabolism, 1988, v. 66 n. 3, p. 611-617 How to Cite?
AbstractWe treated seven GH-deficient children with 3-hourly 1 μg/kg sc pulses of GHRH-(1-44) for 6 months and 2 μg/kg·pulse for another 6 months. Four patients had a serum GH response to iv GHRH before treatment, and an additional patient responded to iv GHRH after 1 month of pulsatile sc GHRH administration. The mean cumulative growth velocity increased from a pretreatment mean of 2.7 ± 0.2 (± SE) to 8.4 ± 2.5 and 5.4 ± 0.7 cm/yr after 2 months and 1 yr of treatment, respectively. Low dose pulsatile GHRH therapy was effective in promoting growth in five of seven children, with height gain ranging from 4.4-7.5 cm at the end of 1 yr's therapy. Only one of the two patients who did not respond to GHRH had an improvement in linear growth when they were subsequently treated with synthetic GH. The other patient, a 16.5-yr-old pubertal girl who had both satisfactory GH and somatomedin-C responses during GHRH therapy, did not respond to either GHRH or, later, synthetic GH. The pretreatment serum GH response to iv GHRH, the serum somatomedin-C concentrations, and the peak serum GH response during sc GHRH therapy were not reliable predictors of clinical response.
Persistent Identifierhttp://hdl.handle.net/10722/170232
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.940
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLow, LCKen_US
dc.contributor.authorWang, Cen_US
dc.contributor.authorCheung, PTen_US
dc.contributor.authorHo, Pen_US
dc.contributor.authorLam, KSLen_US
dc.contributor.authorYoung, RTTen_US
dc.contributor.authorYeung, CYen_US
dc.contributor.authorLing, Nen_US
dc.date.accessioned2012-10-30T06:06:52Z-
dc.date.available2012-10-30T06:06:52Z-
dc.date.issued1988en_US
dc.identifier.citationJournal Of Clinical Endocrinology And Metabolism, 1988, v. 66 n. 3, p. 611-617en_US
dc.identifier.issn0021-972Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/170232-
dc.description.abstractWe treated seven GH-deficient children with 3-hourly 1 μg/kg sc pulses of GHRH-(1-44) for 6 months and 2 μg/kg·pulse for another 6 months. Four patients had a serum GH response to iv GHRH before treatment, and an additional patient responded to iv GHRH after 1 month of pulsatile sc GHRH administration. The mean cumulative growth velocity increased from a pretreatment mean of 2.7 ± 0.2 (± SE) to 8.4 ± 2.5 and 5.4 ± 0.7 cm/yr after 2 months and 1 yr of treatment, respectively. Low dose pulsatile GHRH therapy was effective in promoting growth in five of seven children, with height gain ranging from 4.4-7.5 cm at the end of 1 yr's therapy. Only one of the two patients who did not respond to GHRH had an improvement in linear growth when they were subsequently treated with synthetic GH. The other patient, a 16.5-yr-old pubertal girl who had both satisfactory GH and somatomedin-C responses during GHRH therapy, did not respond to either GHRH or, later, synthetic GH. The pretreatment serum GH response to iv GHRH, the serum somatomedin-C concentrations, and the peak serum GH response during sc GHRH therapy were not reliable predictors of clinical response.en_US
dc.languageengen_US
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.orgen_US
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_US
dc.subject.meshAdolescenten_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshGrowth Disorders - Blood - Drug Therapyen_US
dc.subject.meshGrowth Hormone - Blood - Deficiencyen_US
dc.subject.meshGrowth Hormone-Releasing Hormone - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshInsulin-Like Growth Factor I - Blooden_US
dc.subject.meshMaleen_US
dc.titleLong term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiencyen_US
dc.typeArticleen_US
dc.identifier.emailLow, LCK:lcklow@hkucc.hku.hken_US
dc.identifier.emailCheung, PT:ptcheung@hkucc.hku.hken_US
dc.identifier.emailLam, KSL:ksllam@hku.hken_US
dc.identifier.authorityLow, LCK=rp00337en_US
dc.identifier.authorityCheung, PT=rp00351en_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1210/jcem-66-3-611-
dc.identifier.pmid3127420en_US
dc.identifier.scopuseid_2-s2.0-0023857984en_US
dc.identifier.volume66en_US
dc.identifier.issue3en_US
dc.identifier.spage611en_US
dc.identifier.epage617en_US
dc.identifier.isiWOS:A1988M305400024-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLow, LCK=7007049461en_US
dc.identifier.scopusauthoridWang, C=7501631357en_US
dc.identifier.scopusauthoridCheung, PT=7202595465en_US
dc.identifier.scopusauthoridHo, P=7402211336en_US
dc.identifier.scopusauthoridLam, KSL=8082870600en_US
dc.identifier.scopusauthoridYoung, RTT=8959321900en_US
dc.identifier.scopusauthoridYeung, CY=7201354144en_US
dc.identifier.scopusauthoridLing, N=35500564400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats